AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6409917 — intervention group
Group type: COMPARATOR
Intervention: Fasting alone (Control group)
Number of subjects: 24
Study 31419968 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVRR plus Savings plus Financial Literacy (HIVRR + S + FL)
Number of subjects: 990
Study 31419968 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVRR plus Savings plus Financial Literacy plus Vocational Skills Training and Mentorship (HIVRR + S + FL + V)
Number of subjects: 990
Study 31419968 — intervention group
Group type: COMPARATOR
Intervention: Only HIVRR (Control group)
Number of subjects: 990
Study 28229457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxy progesterone injection
Number of subjects: 78
Study 28229457 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide injection
Number of subjects: 78
Study 27614989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine
Number of subjects: 30
Study 27614989 — intervention group
Group type: COMPARATOR
Intervention: Syringe lidocaine
Number of subjects: 30
Study 25683037 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) once daily
Number of subjects: 350
Study 25683037 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir (IDet) once or twice daily
Number of subjects: 350
Study 23194488 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d rosuvastatin
Number of subjects: 1462
Study 23194488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1462
Study 20526152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral microdecompressive laminatomy (MDL)
Number of subjects: 71
Study 20526152 — intervention group
Group type: COMPARATOR
Intervention: Total laminectomy (TL)
Number of subjects: 71
Study 18540935 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching the video screen during the procedure
Number of subjects: 154
Study 18540935 — intervention group
Group type: COMPARATOR
Intervention: Not watching the video screen during the procedure
Number of subjects: 154
Study 15786754 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.07 mL/kg body weight/sec over 30 sec at an iodine concentration of 300 mgI/mL (Group 1)
Number of subjects: 124
Study 15786754 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.06 mL/kg body weight/sec over 30 sec at an iodine concentration of 350 mgI/mL (Group 2)
Number of subjects: 124
Study 15786754 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast injection at 0.07 mL/kg body weight/sec over 25.7 sec at an iodine concentration of 350 mgI/mL (Group 3)
Number of subjects: 124
Study 12424549 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam
Number of subjects: 33
Study 12424549 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oxazepam
Number of subjects: 33
Study 12424549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10349120 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline group: 0.45% saline solution I.V., 1.5 cc/kg/min, 6 hours before and after the angiographic study
Number of subjects: 75
Study 10349120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopa group: 0.45% saline solution I.V. plus dopamine 2 micrograms/kg/min, 30 minutes before the study until termination
Number of subjects: 75
Study 10349120 — intervention group
Group type: COMPARATOR
Intervention: CONTROL GROUP: without interventions
Number of subjects: 75
Study 7756151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05‐0.1% tretinoin cream (Retin A, Ortho)
Number of subjects: 4
Study 7756151 — intervention group
Group type: COMPARATOR
Intervention: Purpose cream (vehicle control)
Number of subjects: 4
Study 2192553 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide hydrochloride (8 mg daily dosage limit, 40 ml)
Number of subjects: 0
Study 2192553 — intervention group
Group type: COMPARATOR
Intervention: Bismuth subsalicylate (4.9 g daily dosage limit)
Number of subjects: 0
Study 794716 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone plus behavior therapy
Number of subjects: 29
Study 794716 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone alone
Number of subjects: 29
Study 31822034 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS-3 score of 0
Number of subjects: 0
Study 31822034 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS-3 score of 1
Number of subjects: 0
Study 31822034 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS-3 score of 2
Number of subjects: 0
Study 31822034 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS-3 score of 3
Number of subjects: 0
Study 31540724 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine dermal patch augmentation
Number of subjects: 92
Study 31540724 — intervention group
Group type: COMPARATOR
Intervention: Standard medialized single-row repair
Number of subjects: 92
Study 27335088 — intervention group
Group type: EXPERIMENTAL
Intervention: True moxibustion
Number of subjects: 16
Study 27335088 — intervention group
Group type: COMPARATOR
Intervention: Sham moxibustion
Number of subjects: 16
Study 25493953 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network score (SNS)
Number of subjects: 6972
Study 25493953 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 6972
Study 25493953 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 6972
Study 25493953 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 6972
Study 23070057 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day for 30 days)
Number of subjects: 12
Study 23070057 — intervention group
Group type: COMPARATOR
Intervention: Control group (fertile women)
Number of subjects: 12
Study 23070057 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including controls)
Number of subjects: 12
Study 21724007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid laryngoscope
Number of subjects: 40
Study 21724007 — intervention group
Group type: COMPARATOR
Intervention: Lighted stylet
Number of subjects: 40
Study 21724007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 19635719 — intervention group
Group type: COMPARATOR
Intervention: rilonacept (IL1 Trap)
Number of subjects: 10
Study 22404426 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 0
Study 15997021 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 1834
Study 15997021 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective serotonin reuptake inhibitor antidepressants
Number of subjects: 1834
Study 12885981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (28%) before exercise
Number of subjects: 52
Study 12885981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (28%) after exercise
Number of subjects: 52
Study 12885981 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 52
Study 9491504 — intervention group
Group type: EXPERIMENTAL
Intervention: MN rgp160 vaccine (200 μg doses)
Number of subjects: 24
Study 9491504 — intervention group
Group type: EXPERIMENTAL
Intervention: MN rgp160 vaccine (800 μg fourth dose)
Number of subjects: 24
Study 9491504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9098468 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate (CC) treatment
Number of subjects: 70
Study 2759843 — intervention group
Group type: EXPERIMENTAL
Intervention: Group administered CBT
Number of subjects: 22
Study 2759843 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually administered CBT
Number of subjects: 22
Study 2759843 — intervention group
Group type: COMPARATOR
Intervention: No treatment (wait list) control
Number of subjects: 22
Study 931393 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroform
Number of subjects: 50
Study 931393 — intervention group
Group type: COMPARATOR
Intervention: Camphor-in-oil placebo
Number of subjects: 50
Study 12468785 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 42
Study 12468785 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients (historical control from NASCET)
Number of subjects: 42
Study 29759063 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol and NSAIDs (specific dosages and duration not mentioned)
Number of subjects: 4
Study 29759063 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 4
Study 26321037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 1180
Study 26321037 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1180
Study 25064723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 368
Study 25064723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 368
Study 25064723 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab or Bevacizumab (both treatments)
Number of subjects: 368
Study 25064723 — intervention group
Group type: COMPARATOR
Intervention: Baseline features
Number of subjects: 368
Study 22774615 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengjing Tablets
Number of subjects: 150
Study 22774615 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E capsules (control group)
Number of subjects: 150
Study 20669816 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% strontium acetate, 1040 ppm sodium fluoride dentifrice
Number of subjects: 79
Study 20669816 — intervention group
Group type: COMPARATOR
Intervention: 8% arginine, calcium carbonate, 1450 ppm sodium monofluorophosphate dentifrice
Number of subjects: 79
Study 20669816 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 79
Study 18555575 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebaudioside A (1000mg)
Number of subjects: 60
Study 18555575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16234429 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive (up to $0.50)
Number of subjects: 85671
Study 16234429 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive ($0.50 - $5.00)
Number of subjects: 85671
Study 11893863 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics
Number of subjects: 20
Study 11893863 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical neuroleptics
Number of subjects: 20
Study 11893863 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 11893863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both typical and atypical neuroleptics
Number of subjects: 20
Study 10458052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical multidimensional model with three or four first-order factors
Number of subjects: 507
Study 10458052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical model with four first-order factors
Number of subjects: 507
Study 10458052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical model with three first-order factors
Number of subjects: 507
Study 8903629 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (1 mu g/kg body weight subcutaneously, twice a day at 0800 and 1800 h)
Number of subjects: 18
Study 8903629 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 18
Study 2633238 — intervention group
Group type: EXPERIMENTAL
Intervention: Pellet pancreatin (9 pellets/day)
Number of subjects: 30
Study 2633238 — intervention group
Group type: COMPARATOR
Intervention: Tablet pancreatin (12 tablets/day)
Number of subjects: 30
Study 323298 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg triamterene plus 25 mg hydrochlorothiazide
Number of subjects: 0
Study 323298 — intervention group
Group type: COMPARATOR
Intervention: 25 mg spironolactone plus 25 mg hydrochlorothiazide
Number of subjects: 0
Study 31923177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin plus phenobarbital
Number of subjects: 90
Study 31923177 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital alone
Number of subjects: 90
Study 30464234 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (n = 14), three 50‐min sessions weekly from 16 weeks gestation to delivery
Number of subjects: 36
Study 30464234 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (n = 14)
Number of subjects: 36
Study 30464234 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (n = 22)
Number of subjects: 36
Study 26422394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalved cast immobilization
Number of subjects: 202
Study 26422394 — intervention group
Group type: COMPARATOR
Intervention: Circumferential cast immobilization
Number of subjects: 202
Study 25920599 — intervention group
Group type: EXPERIMENTAL
Intervention: PDRN injection
Number of subjects: 40
Study 25920599 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (placebo)
Number of subjects: 40
Study 24019047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) - one Fleet enema on the morning of surgery
Number of subjects: 40
Study 24019047 — intervention group
Group type: COMPARATOR
Intervention: Non-mechanical bowel preparation (non-MBP) - no enema before surgery
Number of subjects: 40
Study 21474338 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular approach for subclavian vein (n = 65)
Number of subjects: 195
Study 21474338 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular approach for subclavian vein (n = 65)
Number of subjects: 195
Study 21474338 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular vein approach (n = 65)
Number of subjects: 195
Study 19663521 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg once daily for 1 year
Number of subjects: 72
Study 19663521 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg once daily for 1 year
Number of subjects: 72
Study 16788808 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral immunonutrition (iEN)
Number of subjects: 326
Study 16788808 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 326
Study 12684363 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet plus behavioral e‐counseling program
Number of subjects: 92
Study 12684363 — intervention group
Group type: COMPARATOR
Intervention: Basic Internet program
Number of subjects: 92
Study 10980875 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa receptor blockade
Number of subjects: 0
Study 10980875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8623742 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 21
Study 8623742 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 21
Study 1446142 — intervention group
Group type: EXPERIMENTAL
Intervention: GR32191, 40 mg four times daily for 3 weeks
Number of subjects: 9
Study 1446142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6152435 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (0.075 U/kg body weight)
Number of subjects: 6
Study 6152435 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin (0.075 U/kg body weight)
Number of subjects: 6
Study 6152435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine insulin (0.075 U/kg body weight)
Number of subjects: 6
Study 6152435 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (100 micrograms/h)
Number of subjects: 6
Study 30997499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (1.25-1.75 L of beverage sweetened with sucrose daily for 12 weeks)
Number of subjects: 154
Study 30997499 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharin (1.25-1.75 L of beverage sweetened with saccharin daily for 12 weeks)
Number of subjects: 154
Study 30997499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (1.25-1.75 L of beverage sweetened with sucralose daily for 12 weeks)
Number of subjects: 154
Study 30997499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (1.25-1.75 L of beverage sweetened with aspartame daily for 12 weeks)
Number of subjects: 154
Study 30997499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebaudioside A (1.25-1.75 L of beverage sweetened with rebA daily for 12 weeks)
Number of subjects: 154
Study 28691202 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 82
Study 28691202 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 82
Study 30627512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic venous ulcers (CULEs) in diabetic patients
Number of subjects: 85
Study 30627512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic venous ulcers (CULEs)
Number of subjects: 85
Study 24872261 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed interlocking intramedullary nail
Number of subjects: 40
Study 24872261 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 40
Study 22424018 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) of the occluded infarct-related artery
Number of subjects: 484
Study 22424018 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 484
Study 22424018 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 484
Study 20649060 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate with potassium salt (GS‐K) 1500 mg daily
Number of subjects: 90
Study 20649060 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine sulfate with sodium salt (GS‐Na) 1500 mg daily
Number of subjects: 90
Study 18379501 — intervention group
Group type: EXPERIMENTAL
Intervention: Semax (1% solution)
Number of subjects: 27
Study 16076940 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 1,25-dihydroxyvitamin D
Number of subjects: 93
Study 16076940 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH
Number of subjects: 93
Study 16076940 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-OHD
Number of subjects: 93
Study 12384844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (Nvp), stavudine (d4T), and indinavir (Idv; 1000 mg 3 times daily)
Number of subjects: 145
Study 12384844 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (3TC), stavudine (d4T), and indinavir (Idv; 800 mg 3 times daily)
Number of subjects: 145
Study 12384844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (Nvp)
Number of subjects: 145
Study 12384844 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (3TC)
Number of subjects: 145
Study 10562790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 40
Study 10562790 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 40
Study 8909210 — intervention group
Group type: EXPERIMENTAL
Intervention: Single running 10-0 nylon suture with postoperative suture tension adjustment (Group 1)
Number of subjects: 32
Study 8909210 — intervention group
Group type: COMPARATOR
Intervention: Combined running and interrupted 10-0 nylon sutures with selective postoperative removal of interrupted sutures (Group 2)
Number of subjects: 32
Study 1809720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser treatment (GAAS pulsed laser)
Number of subjects: 40
Study 1809720 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 40
Study 6853932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (8 mg/kg)
Number of subjects: 19
Study 6853932 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 19
Study 6853932 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (240 micrograms)
Number of subjects: 19
Study 28902034 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,060-nm diode laser treatment
Number of subjects: 49
Study 29129191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abstinence behavioral intervention
Number of subjects: 239
Study 25839918 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular decompression (MVD)
Number of subjects: 78
Study 25839918 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon compression (BC)
Number of subjects: 78
Study 25839918 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 78
Study 25839918 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 78
Study 24004891 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange-fleshed sweet potatoes (12 mg β-carotene/d)
Number of subjects: 135
Study 24004891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangerines (5.3 mg β-cryptoxanthin/d)
Number of subjects: 135
Study 24004891 — intervention group
Group type: EXPERIMENTAL
Intervention: White-fleshed sweet potatoes with a vitamin A supplement (0.5 mg/d)
Number of subjects: 135
Study 24004891 — intervention group
Group type: COMPARATOR
Intervention: White-fleshed sweet potatoes 2 times/d, 6 d/wk for 3 wk
Number of subjects: 135
Study 20189491 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM administered concomitantly with Tdap and HPV vaccines
Number of subjects: 1620
Study 20189491 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM administered sequentially with Tdap and HPV vaccines
Number of subjects: 1620
Study 18946011 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdental brushing
Number of subjects: 0
Study 18946011 — intervention group
Group type: COMPARATOR
Intervention: Flossing
Number of subjects: 0
Study 16981000 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h infusion of CsA 3 mg/kg/day
Number of subjects: 21
Study 16981000 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of CsA 3 mg/kg/day
Number of subjects: 21
Study 15239026 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (1 mg pre-meal 3 x/day) + Metformin (2550 mg/day)
Number of subjects: 11
Study 10908008 — intervention group
Group type: EXPERIMENTAL
Intervention: Research conducted in community treatment organizations
Number of subjects: 0
Study 9368727 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART)
Number of subjects: 526
Study 9368727 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 526